VNDA

4.35

0.69% 0.03

Dopo l'orario di chiusura: 4.43 0.08 +1.84%

Vanda Pharmaceuticals Inc (VNDA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$4.32

Aprire:

$4.36

Volume 24 ore:

1.12M

Relative Volume:

2.07

Capitalizzazione di mercato:

$257.04M

Reddito:

$192.64M

Utile/perdita netta:

$2.51M

Rapporto P/E:

83.02

EPS:

0.0524

Flusso di cassa netto:

$12.42M

1 W Prestazione:

-20.91%

1M Prestazione:

-12.83%

6M Prestazione:

-3.55%

1 anno Prestazione:

-6.45%

Intervallo 1D:

$4.28

$4.51

Intervallo di 1 settimana:

$4.28

$5.70

Portata 52W:

$3.8092

$5.70

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Nome

Vanda Pharmaceuticals Inc

Settore

Healthcare (1135)

Industria

Biotechnology (635)

Telefono

202-734-3400

Indirizzo

2200 PENNSYLVANIA AVE NW, WASHINGTON

Dipendente

368

Cinguettio

Prossima data di guadagno

2025-05-02

Ultimi documenti SEC

VNDA's Discussions on Twitter

Confronta VNDA con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VNDA Vanda Pharmaceuticals Inc	4.35	255.27M	192.64M	2.51M	12.42M	0.0524
VRTX Vertex Pharmaceuticals Inc	425.57	107.66B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	651.80	68.74B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	456.04	58.93B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	818.50	50.51B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	189.60	41.29B	447.02M	-1.18B	-868.57M	-6.1812

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-10-31	Iniziato	H.C. Wainwright	Buy
2024-07-11	Iniziato	Cantor Fitzgerald	Overweight
2022-02-25	Downgrade	Jefferies	Buy → Hold
2021-05-12	Iniziato	BofA Securities	Buy
2021-01-14	Downgrade	Citigroup	Buy → Neutral
2020-10-29	Aggiornamento	Citigroup	Neutral → Buy
2020-06-09	Downgrade	Citigroup	Buy → Neutral
2020-03-16	Downgrade	Oppenheimer	Perform → Underperform
2020-03-12	Aggiornamento	Citigroup	Neutral → Buy
2019-11-07	Downgrade	Citigroup	Buy → Neutral
2019-08-01	Aggiornamento	Citigroup	Neutral → Buy
2019-07-25	Downgrade	Stifel	Buy → Hold
2018-12-11	Downgrade	Oppenheimer	Outperform → Perform
2018-12-04	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2018-12-04	Reiterato	Jefferies	Buy
2018-11-08	Ripresa	Jefferies	Buy
2018-09-21	Ripresa	Oppenheimer	Outperform
2018-05-23	Iniziato	Citigroup	Buy
2018-01-19	Iniziato	Seaport Global Securities	Buy
2017-09-14	Reiterato	Piper Jaffray	Overweight
2017-06-27	Ripresa	Piper Jaffray	Overweight
2017-05-26	Iniziato	H.C. Wainwright	Buy
2017-04-12	Iniziato	Oppenheimer	Outperform
2016-11-09	Iniziato	Aegis Capital	Buy
2016-10-06	Ripresa	Jefferies	Buy

Mostra tutto

Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie

11:39 AM

Backtesting results for Vanda Pharmaceuticals Inc. trading strategiesJuly 2025 Drop Watch & Fast Entry High Yield Stock Tips - newser.com

11:39 AM

10:12 AM

Assessing Vanda Pharmaceuticals (VNDA) Valuation After Q3 2025 Growth and Updated FDA Milestones - Yahoo Finance

10:12 AM

07:48 AM

Visualizing Vanda Pharmaceuticals Inc. stock with heatmapsMarket Activity Report & Daily Profit Maximizing Trade Tips - newser.com

07:48 AM

07:33 AM

Is Vanda Pharmaceuticals Inc. stock safe for conservative investorsMarket Trend Report & Fast Moving Stock Trade Plans - newser.com

07:33 AM

06:46 AM

How institutional buying supports Vanda Pharmaceuticals Inc. stock2025 Top Decliners & Smart Swing Trading Techniques - newser.com

06:46 AM

05:59 AM

News impact scoring models applied to Vanda Pharmaceuticals Inc.July 2025 Recap & Free Daily Entry Point Trade Alerts - newser.com

05:59 AM

01:52 AM

Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded by Wall Street Zen to Hold Rating - MarketBeat

01:52 AM

Nov 01, 2025

Can Vanda Pharmaceuticals Inc. stock deliver surprise earnings beatTreasury Yields & Daily Market Momentum Tracking - newser.com

Nov 01, 2025

Oct 31, 2025

Vanda Pharmaceuticals Reports Strong Sales Growth and Pipeline Progress - MSN

Oct 31, 2025

Cantor Fitzgerald Cuts Vanda Pharmaceuticals (NASDAQ:VNDA) Price Target to $11.00 - MarketBeat

Oct 31, 2025

Jim Cramer on Vanda Pharmaceuticals: “I’m Going to Bless That One as Your Spec” - MSN

Oct 31, 2025

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2025 Earnings Call Transcript - Insider Monkey

Oct 31, 2025

Vanda Pharmaceuticals Q3 Earnings Preview - MSN

Oct 31, 2025

Published on: 2025-10-31 05:46:53 - newser.com

Oct 31, 2025

Applying big data sentiment scoring on Vanda Pharmaceuticals Inc.2025 Growth vs Value & Low Risk Profit Maximizing Plans - newser.com

Oct 31, 2025

Real time pattern detection on Vanda Pharmaceuticals Inc. stockQuarterly Profit Review & Consistent Return Strategy Ideas - newser.com

Oct 31, 2025

Vanda Pharmaceuticals Inc. stock retracement – recovery analysis - newser.com

Oct 31, 2025

Will Vanda Pharmaceuticals Inc. stock recover after recent dropShare Buyback & Weekly Watchlist for Consistent Profits - newser.com

Oct 31, 2025

Can Vanda Pharmaceuticals Inc. recover in the next quarterWeekly Investment Report & Reliable Entry Point Alerts - newser.com

Oct 31, 2025

Will Vanda Pharmaceuticals Inc. (VM4) stock remain on Wall Street radarExit Point & Momentum Based Trading Ideas - newser.com

Oct 31, 2025

Is Vanda Pharmaceuticals Inc. (VM4) stock considered safe havenBond Market & AI Driven Price Forecasts - newser.com

Oct 31, 2025

Smart tools for monitoring Vanda Pharmaceuticals Inc.’s price actionWeekly Gains Summary & Scalable Portfolio Growth Methods - newser.com

Oct 31, 2025

How Vanda Pharmaceuticals Inc. stock performs in interest rate cyclesMarket Volume Report & High Win Rate Trade Alerts - newser.com

Oct 31, 2025

How supply shortages influence Vanda Pharmaceuticals Inc. (VM4) stock2025 Top Gainers & Verified Entry Point Signals - newser.com

Oct 31, 2025

Oct 30, 2025

Vanda Pharmaceuticals (VNDA): Revenue Projected to Grow 22.7% Annually, Profitability in Focus Ahead of Earnings - Yahoo Finance

Oct 30, 2025